VANCOUVER, BC, Aug. 15, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, released its second quarter financial results and operational highlights for the period ended June 30, 2022. “We are pleased to report on another highly productive quarter,” said Filament CEO Benjamin Lightburn.
